Market Cap 80.97M
Revenue (ttm) 0.00
Net Income (ttm) -73.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 118,000
Avg Vol 283,722
Day's Range N/A - N/A
Shares Out 67.48M
Stochastic %K 17%
Beta -0.10
Analysts Strong Sell
Price Target $10.00

Latest News on CLYM

Climb Bio to Present at Upcoming Investor Conferences

Feb 25, 2025, 7:00 AM EST - 5 weeks ago

Climb Bio to Present at Upcoming Investor Conferences


Climb Bio to be Added to the Nasdaq Biotechnology Index

Dec 19, 2024, 7:00 AM EST - 3 months ago

Climb Bio to be Added to the Nasdaq Biotechnology Index


Climb Bio Appoints Douglas E. Williams, Ph.D.

Nov 11, 2024, 7:00 AM EST - 5 months ago

Climb Bio Appoints Douglas E. Williams, Ph.D.


Climb Bio to Host Virtual Investor Event on October 15, 2024

Oct 3, 2024, 10:00 AM EDT - 6 months ago

Climb Bio to Host Virtual Investor Event on October 15, 2024


Eliem Therapeutics Announces Additions to its Leadership Team

Aug 26, 2024, 7:00 AM EDT - 7 months ago

Eliem Therapeutics Announces Additions to its Leadership Team


Eliem Therapeutics Reports Second Quarter Financial Results

Aug 14, 2024, 6:05 AM EDT - 8 months ago

Eliem Therapeutics Reports Second Quarter Financial Results


Eliem Therapeutics Provides Update on Pipeline Progress

Oct 5, 2022, 7:00 AM EDT - 2 years ago

Eliem Therapeutics Provides Update on Pipeline Progress


Eliem Therapeutics Provides ETX-810 Program Update

Aug 2, 2022, 7:00 AM EDT - 2 years ago

Eliem Therapeutics Provides ETX-810 Program Update


Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs

Apr 25, 2022, 7:00 AM EDT - 3 years ago

Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs


Eliem Therapeutics to Present at Stifel's 2022 CNS Days

Mar 21, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics to Present at Stifel's 2022 CNS Days